Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_39bf0bb8b07e151d4bcead749d7dd699 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2730-00071 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2730-10134 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24143 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24141 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10341 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-292 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-02 |
filingDate |
2018-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_767cd2ccced8c718cd1af9323d01ce17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9d65f878fd4cb6b73f5e2ee2888c73f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89d107fd1c034529396fbedb42d74b23 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5895bec5d5c748f83388af832ff64458 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a844c15dc77113aee3f57514216de1e4 |
publicationDate |
2019-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CA-3084281-A1 |
titleOfInvention |
Hepatitis b immunisation regimen and compositions |
abstract |
There is provided a method of treating chronic hepatitis B infection (CHB) in a human, comprising the steps of: a )administering to the human a composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); b) administering to the human a composition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); and c) administering to the human a composition comprising a recombinant hepatitis B surface antigen (HBs), recombinant hepatitis B virus core antigen (HBc) and an adjuvant. |
priorityDate |
2017-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |